Aminoanalytica
AI-enabled, field-ready diagnostics for emerging biological threats, supporting earlier pandemic detection and response
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-10
About Aminoanalytica
AminoAnalytica develops field-ready diagnostics for emerging biological threats, aiming to shorten development timelines. Its work combines AI and computational bionanotechnology.
The company is based in London and was founded in 2024. Its team includes co-founders Abhi and Adam and Chief Scientist Prof. Stefano Angioletti-Uberti; it describes itself as VC-backed and recruits for scientific and engineering backgrounds.
Product: Field-ready diagnostics for emerging biological threats, developed using AI and computational bionanotechnology.
Jobs at Aminoanalytica
More biotech & pharma companies
Amo Pharma
Develops investigational treatments for serious diseases, particularly rare genetic disorders, for patients with unmet medical needsNew on EvolcAmped PCR
QPCR reagents and custom formulations for research labs, assay developers and molecular testing partnersYoung companyNew on EvolcAmphista Therapeutics
Develops Targeted Glue protein-degrader medicines for cancer, with a lead acute myeloid leukemia candidate in Phase 1New on EvolcAnanda Pharma
Develops cannabinoid-based medicines for inflammatory pain conditions and heart failureNew on EvolcAndrolabs
Men's health medicines, including testosterone replacement and erectile dysfunction therapies, for patients and healthcare professionalsNew on EvolcAntigenika
Developing an oral, broad-spectrum snakebite treatment for people in regions with limited access to hospital antivenomYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.